Theravance, Inc. (THRX) Company Profile - CorporateInformation.com


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

Theravance, Inc. Company Snapshot

Business Description:

Theravance, Inc. operates in the Pharmaceutical preparations sector. Theravance, Inc. (Theravance) is a biopharmaceutical company with a pipeline of internally discovered product candidates. As of December 31, 2010, the Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas, including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its programs include VIBATIV (telavancin) with Astellas Pharma Inc. (Astellas) and its RELOVAI program (formerly referred to as Horizon) and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program with GlaxoSmithKline plc (GSK). In our complete report available for purchase the company is compared to: Keryx Biopharmaceuticals, Inc., Sunwin International Neutraceuticals, Inc. and Geopharma, Inc..

Theravance, Inc.

Stock Data:

Recent Stock Performance:

Current Price (2/3/2012): 18.60
(Figures in U.S. Dollars)

1 Week	-1.2%	13 Weeks	-7.9%

4 Weeks	-16.6%	52 Weeks	-24.3%

Theravance, Inc. Key Data:

Ticker:	THRX	Country:	UNITED STATES

Exchanges:	NAS	Major Industry:	Drugs, Cosmetics & Health Care

		Sub Industry:	Ethical Drug Manufacturers

2010 Sales	24,223,000 (Year Ending Jan 2011).	Employees:	193

Currency:	U.S. Dollars	Market Cap:	1,582,958,916

Fiscal Yr Ends:	December	Shares Outstanding:	85,128,202

Share Type:	Common	Closely Held Shares:	50,836,548

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.